» Articles » PMID: 22938746

Retrolective Studies on the Survival of Cancer Patients Treated with Mistletoe Extracts: a Meta-analysis

Overview
Journal Explore (NY)
Publisher Elsevier
Date 2012 Sep 4
PMID 22938746
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies reveal that patients with cancer are actively seeking supportive treatments and may use distinct coping strategies that might be helpful to extend survival time. In this respect, retrolective studies have been applied to examine the therapeutic potential of adjuvant mistletoe treatment.

Material And Methods: The databases PubMed, EMBASE, AMED, and CAMbase were used to identify retrolective studies in mistletoe treatment. In addition to a review, we also performed a meta-analysis with respect to cancer patients' survival time by a random effects model. Overall estimates of treatment effects were displayed with a forest plot.

Results: A total of 17 articles met the inclusion criteria. From these, 10 duplicates and 3 descriptive literature and popular articles had to be removed, leaving 4 retrolective studies on mistletoe preparations and patients' survival conducted between 1985 and 2002, with a total of 3.324 patients (2.454 per protocol) recruited in 17 to 35 German and Swiss hospitals, wards, and private practices. Meta-analysis revealed a moderate overall effect of hazard ratios 0.59 (95% confidence interval 0.50-0.70) in favor of mistletoe treatment.

Discussion: Although we found a positive treatment effect, there are several methodological limitations with respect to the retrolective study design.

Citing Articles

Systematic assessment of the influence of quality of studies on mistletoe in cancer care on the results of a meta-analysis on overall survival.

Hofinger J, Kaesmann L, Buentzel J, Scharpenberg M, Huebner J J Cancer Res Clin Oncol. 2024; 150(4):219.

PMID: 38679615 PMC: 11056339. DOI: 10.1007/s00432-024-05742-1.


Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with L. Therapy in Addition to PD-1/PD-L1 Blockade: A Real-World Data Study.

Schad F, Thronicke A, Hofheinz R, Matthes H, Grah C Cancers (Basel). 2024; 16(8).

PMID: 38672690 PMC: 11049173. DOI: 10.3390/cancers16081609.


Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On L: A Multicenter Real-World Study.

Thronicke A, Matthes B, von Trott P, Schad F, Grah C Integr Cancer Ther. 2020; 19:1534735420940384.

PMID: 32856476 PMC: 7457695. DOI: 10.1177/1534735420940384.


Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.

Thronicke A, Reinhold T, von Trott P, Grah C, Matthes B, Matthes H PLoS One. 2020; 15(7):e0236426.

PMID: 32716969 PMC: 7384610. DOI: 10.1371/journal.pone.0236426.


Statement to an Insufficient Systematic Review on L. Therapy.

Matthes H, Thronicke A, Hofheinz R, Baars E, Martin D, Huber R Evid Based Complement Alternat Med. 2020; 2020:7091039.

PMID: 32148549 PMC: 7049420. DOI: 10.1155/2020/7091039.